Omeicos Therapeutics, a biopharmaceutical spinout of research institute Max Delbrück Center for Molecular Medicine, achieved a first close of its series B round at €8.3m ($8.7m) on Wednesday.
The round was co-led by Vesalius Biocapital and plant construction company SMS Group.
German state-owned development bank KFW and public-private partnership High-Tech Gründerfonds (HTGF) and Ascension, a tech transfer office for a range of German universities, hospitals and institutes, also participated, as did VC Fonds Technologie Berlin, Falck Revocable Trust and members of Omeicos’ management team.
Omeicos is working on treatments for inflammatory, cardiovascular and other diseases. The company is exploiting research conducted by Wolf-Hagen Schunck, John. Falck, Dominik Müller and Robert Fischer.
The money will support a phase 1 clinical trial for the company’s lead candidate, OMT-28, that targets atrial fibrillation, the most common type of cardiac arrhythmia.
Vesalius previously also led a €6.2m series A round in 2015, with participation from SMS, VC Fonds Technologie Berlin, HTGF and KfW.
– This article first appeared on our sister site Global Government Venturing.